Clinical Trials on Post-essential Thrombocythemia Myelofibrosis in France

Total 52 results

AstraZeneca
University of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...

Completed

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Primary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia Myelofibrosis

United States, France
Novartis Pharmaceuticals

Completed

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Idiopathic Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia-Vera Myelofibrosis

United Kingdom, Ireland, Germany, Italy, France
GlaxoSmithKline

Active, not recruiting

Extended Access of Momelotinib in Adults With Myelofibrosis

Neoplasms | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States, Hungary, Israel, Spain, Taiwan, France, Australia, Germany, Belgium, Canada, Singapore, Korea, Republic of, United Kingdom, Denmark, Austria, Romania, Italy, Bulgaria, Poland, Netherlands
Sierra Oncology LLC - a GSK company

Completed

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Canada, Germany, Australia
Incyte Corporation

Recruiting

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders (LIMBER)

Anemia | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, France, Italy, Japan, United Kingdom, Canada
Incyte Corporation

Active, not recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
Sierra Oncology, Inc.

Completed

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria
Sierra Oncology, Inc.

Completed

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (Simplify 2)

Primary Myelofibrosis (PMF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Post-polycythemia Vera (Post-PV)

United States, Canada, France, Italy, Germany, Spain, Israel, United Kingdom
Incyte Corporation

Completed

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States
Incyte Corporation

Active, not recruiting

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, China, Japan, France, Turkey, Germany, Israel, Poland, Belgium, Italy, Austria, Denmark, Finland, Norway
Constellation Pharmaceuticals

Active, not recruiting

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (MANIFEST-2)

Primary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, United States, Canada, Taiwan, Czechia, United Kingdom, Australia, Italy, Belgium, Germany, France, Israel, Greece, Malaysia, Netherlands, Austria, Turkey, Poland, Thailand, Hong Kong, Hungary
CTI BioPharma

Completed

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post- Essential Thrombocythemia Myelofibrosis

United States, Spain, United Kingdom, Hungary, Korea, Republic of, France, Italy, Sweden
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
Sierra Oncology LLC - a GSK company

Completed

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Primary Myelofibrosis (PMF) | Post-polycythemia Vera (Post-PV) Myelofibrosis | Postessential Thrombocythemia (Post-ET) Myelofibrosis

United States, Canada
Sierra Oncology LLC - a GSK company

Completed

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Canada, Hungary, Israel, Spain, United States, Australia, Taiwan, Singapore, Germany, Italy, France, Belgium, New Zealand, Austria, United Kingdom, Denmark, Bulgaria, Poland, Czechia, Romania, Sweden
CTI BioPharma
PSI CRO

Recruiting

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, Canada, Czechia, United States, Australia, France, Hungary, United Kingdom, Romania, Belarus, Bulgaria, Georgia, Germany, Israel, Italy, Poland, Russian Federation, Serbia, Ukraine, Bosnia and Herzegovina and more
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (PAC326)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
Hoffmann-La Roche

Completed

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Netherlands, Italy, United Kingdom, Canada, France, Germany, Israel
Kartos Therapeutics, Inc.

Recruiting

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera MF (Post-PV-MF) | Post-Essential Thrombocythemia MF (Post-ET-MF)

United States, Korea, Republic of, Germany, Australia, Hungary, France, Spain, Italy, Taiwan, Thailand, Brazil, Poland, Turkey, Israel, Portugal, Romania, Argentina, Bulgaria, Canada, Croatia, Czechia, Lithuania, Mexico, Philippines, United... and more
University Hospital, Angers

Recruiting

Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. (BioScoreSMP)

Essential Thrombocythemia | Myeloproliferative Disorder | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

France
University Hospital, Angers
Ligue contre le cancer, France

Recruiting

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) (CALRSUIVI)

Essential Thrombocythemia | Myeloproliferative Neoplasm | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

France
Hospices Civils de Lyon

Completed

Prospective Study of Different Biological Tests (Multiplate, ROTEM) in a Cohort of Patients Followed for Essential Thrombocytemia (ET) (THETE)

Thrombocythemia Essential

France
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
AOP Orphan Pharmaceuticals AG

Completed

Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia (ANAHYDRET)

Essential Thrombocythaemia

Austria, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Poland, Singapore, Slovenia
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Neoplasms | Myeloproliferative Disorders | Essential Thrombocythemia | Myelofibrosis

United States, Spain, France, Canada
Incyte Corporation

Completed

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

MPN (Myeloproliferative Neoplasms)

United States, Puerto Rico
University Hospital, Brest

Recruiting

Myeloproliferative Neoplastic Diseases Observatory From Brest (OBENE)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

France
University of California, Irvine

Recruiting

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloproliferative Neoplasm | MPN

United States
Kartos Therapeutics, Inc.

Recruiting

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Myelofibrosis

United States, France, Australia, Spain, Germany, Bulgaria, Israel, Italy, Poland
Novartis Pharmaceuticals
Incyte Corporation

Terminated

A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Myelofibrosis

Spain, United Kingdom, Australia, Israel, Germany, Italy, Singapore, Austria, France
University Hospital, Angers

Not yet recruiting

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes (PHEMOP)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

France
University Hospital, Brest

Recruiting

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (AVAJAK)

Polycythemia Vera | Essential Thrombocythemia | High-risk Patients | Prefibrotic/Early Primary Myelofibrosis | JAK2 V617F

France
Novartis Pharmaceuticals

Completed

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Myelofibrosis

France, United Kingdom, Belgium, Germany, Netherlands, Italy, Austria, Spain, Sweden
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Terminated

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Essential Thrombocythemia

France
Shire

Completed

Pediatric Disease Registry in Essential Thrombocythaemia (ET)

Essential Thrombocythemia (ET)

United Kingdom, Italy, Czechia, France, Germany, Greece, Spain, Switzerland
Assistance Publique - Hôpitaux de Paris

Unknown

Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia (FAST)

Essential Thrombocythemia | MPN

France
Incyte Corporation

Completed

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

MPN (Myeloproliferative Neoplasms)

United States
Shire

Completed

A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients

Thrombocythemia, Hemorrhagic

Bulgaria, France, Hungary, Poland, Portugal, Serbia
University Hospital, Brest

Completed

Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients (OUEST)

Polycythemia Vera | Essential Thrombocythemia

France
Incyte Corporation

Completed

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

MPN (Myeloproliferative Neoplasms)

United States, Canada, Australia
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
Ronald Hoffman
National Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...

Completed

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

High Risk Polycythemia Vera | High Risk Essential Thrombocythemia

United States, Italy, United Kingdom, France
University Hospital, Bordeaux

Completed

Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms (PhiNESS)

Polycythemia Vera | Essential Thrombocythemia

France
Shire

Completed

French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia (FOX)

Essential Thrombocythemia

France
Sierra Oncology, Inc.

Terminated

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Polycythemia Vera | Essential Thrombocythemia

United States, France, Germany, Canada, Australia
Telios Pharma, Inc.

Recruiting

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Primary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET Myelofibrosis

Spain, United States, France, Poland, Italy, Germany
Kartos Therapeutics, Inc.
Telios Pharma, Inc.

Recruiting

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Primary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET Myelofibrosis

United States, Italy, Serbia, Poland, France, Austria, Bulgaria, Germany, Hungary, Spain
Sanofi

Completed

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Hematopoietic Neoplasm

United States, Spain, France, Canada, Australia, Korea, Republic of, Germany, Italy, United Kingdom
Constellation Pharmaceuticals
The Leukemia and Lymphoma Society

Active, not recruiting

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Neoplasms | Neoplasms by Histologic Type | Leukemia | Preleukemia | Primary Myelofibrosis | Myeloproliferative Disorders | Myelofibrosis | Precancerous Conditions | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic Syndrome (MDS) | Leukemia, Myelocytic, Acute | Bone Marrow Disease | Hematological Disease and other conditions

Canada, United States, United Kingdom, Germany, Italy, Belgium, France, Netherlands, Poland
Shire

Completed

Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments

Thrombocythemia, Essential

Spain, United Kingdom, Greece, Denmark, Italy, France, Finland, Norway, Sweden, Germany, Cyprus, Ireland, Netherlands, Portugal

Clinical Trials on Post-essential Thrombocythemia Myelofibrosis in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations